What podcasts say about Adam Vorstein

Every statement, with the speaker, the exact quote and the moment it was said.

What Adam Vorstein has said on podcasts

6 statements · 2 positive · 4 negative

on In-vivo CAR-T developmentNegativeOct 8, 2026· The Readout Loud
In-vivo CAR-T development has crowded out off-the-shelf CAR-T companies such as Caribou.
“they've kind of just boxed out the off-the-shelf companies like Caribou”
Listen at 7:34
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
on Widely owned biotech stocksNegativeOct 8, 2026· The Readout Loud
Widely owned biotech stocks have underperformed, particularly since August.
“many of the biotech stocks that are most commonly owned by both like the specialist funds and even retail investors. You call those the crowded longs, like lots and lots of people own these stocks. They are underperforming, particularly since August.”
Listen at 10:38
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
on Frequently shorted biotech stocksPositiveOct 8, 2026· The Readout Loud
Frequently shorted biotech stocks are outperforming.
“stocks that are often. shorted, meaning investors are betting that the stock prices will go down. Those stocks are actually outperforming.”
Listen at 10:59
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
on ModernaPositiveOct 8, 2026· The Readout Loud
Nearly all Moderna’s XBI gains came after its mRNA cancer-vaccine results.
“Nearly all those gains came since August when the company reported the results of that mRNA cancer vaccine.”
Listen at 11:45
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
on Interest rateNegativeOct 8, 2026· The Readout Loud
Rising interest rates increase biotech companies’ borrowing and fundraising costs.
“interest rates are rising, which makes it more expensive for biotech companies to borrow money, raise money.”
Listen at 12:38
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
on Biotech financingNegativeOct 8, 2026· The Readout Loud
Market turmoil and losses may make investors less willing to finance biotech companies.
“their willingness to finance biotech companies, it can get maybe a little dicier, more difficult for companies to raise money.”
Listen at 13:00
Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.